Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 6/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284781 | 1.00 | HSD11B1 (0.47) | HSD11B1HSD11B2ACHENR1H4CES2 | |
| SCHEMBL18495442 | 0.91 | HSD11B1 (0.42) | HSD11B1HSD11B2ACHENR1H4CES2 | |
| SCHEMBL29843558 | 0.86 | HSD11B1 (0.43) | HSD11B1HSD11B2ACHENR1H4CES2 | |
| SCHEMBL5824299 | 0.84 | HSD11B1 (0.61) | HSD11B1HSD11B2ACHENR1H4CES2 | |
| SCHEMBL4232495 | 0.83 | HSD11B1 (0.62) | HSD11B1HSD11B2ACHEFNTAFNTB | |
| SCHEMBL4232501 | 0.83 | HSD11B1 (0.62) | HSD11B1HSD11B2ACHEFNTAFNTB | |
| SCHEMBL4232633 | 0.76 | HSD11B1 (0.52) | HSD11B1HSD11B2ACHEFNTAFNTB | |
| SCHEMBL29925026 | 0.76 | HSD11B1 (0.52) | HSD11B1HSD11B2ACHEFNTAFNTB | |
| SCHEMBL4232635 | 0.76 | HSD11B1 (0.52) | HSD11B1HSD11B2ACHEFNTAFNTB | |
| SCHEMBL5822876 | 0.72 | HSD11B1 (0.59) | HSD11B1HSD11B2ACHEFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570312-B2 | Method for the separation of the isoprenic constituents of guayule | VERSALIS S.P.A (IT) | 2020-02-25 | — | — | US | disclosed |
| US-20180171178-A1 | METHOD FOR THE SEPARATION OF THE ISOPRENIC CONSTITUENTS OF GUAYULE | VERSALIS S.P.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-20180171178-A1 | METHOD FOR THE SEPARATION OF THE ISOPRENIC CONSTITUENTS OF GUAYULE | VERSALIS S.P.A. (IT) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180171178-A1 | METHOD FOR THE SEPARATION OF THE ISOPRENIC CONSTITUENTS OF GUAYULE | ARGLU1, GUCY1B1, ARG1 | HSD11B1 1614/4885HSD11B2 1919/4885ACHE 1677/4885 |
| US-10570312-B2 | Method for the separation of the isoprenic constituents of guayule | ARGLU1, GUCY1B1, ARG1 | HSD11B1 1614/4885HSD11B2 1919/4885ACHE 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.